Zacks: Analysts Expect Kezar Life Sciences Inc (NASDAQ:KZR) Will Post Earnings of -$0.56 Per Share

Equities analysts expect Kezar Life Sciences Inc (NASDAQ:KZR) to report earnings of ($0.56) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Kezar Life Sciences’ earnings, with the highest EPS estimate coming in at ($0.53) and the lowest estimate coming in at ($0.58). Kezar Life Sciences reported earnings of ($0.30) per share in the same quarter last year, which would indicate a negative year over year growth rate of 86.7%. The company is expected to report its next earnings results on Tuesday, March 24th.

According to Zacks, analysts expect that Kezar Life Sciences will report full-year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($1.91) to ($1.87). For the next year, analysts forecast that the company will report earnings of ($2.13) per share, with EPS estimates ranging from ($2.50) to ($1.50). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Kezar Life Sciences.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.03.

KZR has been the subject of several recent analyst reports. Zacks Investment Research upgraded Kezar Life Sciences from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research note on Tuesday, November 12th. Cowen restated a “buy” rating on shares of Kezar Life Sciences in a research note on Wednesday, November 6th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Kezar Life Sciences in a research note on Monday, October 21st. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $9.13.

Institutional investors have recently made changes to their positions in the company. Victory Capital Management Inc. lifted its position in shares of Kezar Life Sciences by 105.7% during the second quarter. Victory Capital Management Inc. now owns 461,453 shares of the company’s stock worth $3,558,000 after purchasing an additional 237,110 shares during the last quarter. BlackRock Inc. lifted its position in shares of Kezar Life Sciences by 32.9% during the second quarter. BlackRock Inc. now owns 844,391 shares of the company’s stock worth $6,512,000 after purchasing an additional 208,816 shares during the last quarter. Morgan Stanley lifted its position in shares of Kezar Life Sciences by 923.4% during the second quarter. Morgan Stanley now owns 74,982 shares of the company’s stock worth $578,000 after purchasing an additional 67,655 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Kezar Life Sciences by 1,151.2% during the second quarter. JPMorgan Chase & Co. now owns 38,275 shares of the company’s stock worth $275,000 after purchasing an additional 35,216 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Kezar Life Sciences by 302.5% during the second quarter. Wells Fargo & Company MN now owns 30,878 shares of the company’s stock worth $238,000 after purchasing an additional 23,207 shares during the last quarter. Institutional investors own 51.04% of the company’s stock.

NASDAQ KZR traded up $0.10 during trading hours on Wednesday, hitting $2.73. The company had a trading volume of 69,501 shares, compared to its average volume of 94,270. The firm’s 50 day moving average is $3.01 and its 200 day moving average is $5.77. The company has a debt-to-equity ratio of 0.07, a current ratio of 16.67 and a quick ratio of 16.67. The company has a market capitalization of $49.96 million, a price-to-earnings ratio of -1.21 and a beta of 0.78. Kezar Life Sciences has a fifty-two week low of $2.36 and a fifty-two week high of $36.33.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Featured Article: Understanding Average Daily Trade Volume

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.